

Answering the Call: Practical Strategies for Improving Earlier Diagnosis and Patient-Centered Management in Primary Care

Tweetorial #3: Pharmacologic Treatment of COPD

Tweet 4

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 5

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 6

Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). *Eur Respir J.* 2015;45:969-979. doi:10.1183/09031936.00136014

Calverley PMA, de la Hoz A, Xue W, Ferguson GT, Miravitles M. COPD maintenance therapy with tiotropium/olodaterol compared with tiotropium: an analysis in the absence of additional ICS therapy. *COPD.* 2020;17:477-484. doi:10.1080/15412555.2020.1813269

Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. *Lancet Respir Med.* 2018;6(5):337-344. doi:10.1016/S2213-2600(18)30102-4

Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. *Int J Chron Obstruct Pulmon Dis.* 2018;13:2147-2156. doi:10.2147/COPD.S169941

Lipari M, et al. Dual- versus mono-bronchodilator therapy in moderate to severe COPD: a meta-analysis. *Ann Pharmacother.* 2020;54(12):1232-1242. doi:10.1177/1060028020932134

Mammen MJ, Pai V, Aaron DS, et al. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. a systematic review and meta-analysis in support of the american thoracic society clinical practice guideline. *Ann Am Thorac Soc.* 2020;17:1133-1143. doi:10.1513/AnnalsATS.201912-915OC

Maltais F, Bjemer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res.* 2019;20:238. doi:10.1186/s12931-019-1193-9

Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. *Respir Res.* 2016;17:73. doi:10.1186/s12931-016-0387-7

Singh D, D'Urzo AD, Chuecos F, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. *Respir Res.* 2017;18:106. doi:10.1186/s12931-017-0583-0

Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med*. 2013;1:199-209. doi:10.1016/S2213-2600(13)70052-3

Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled analysis of the TONADO®/DYNAGITO® trials. *Adv Ther*. 2020;37:4266-4279.

Tweet 8

National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Updated May 2019. Accessed June 2022.
<https://www.nice.org.uk/guidance/ng115>

Tweet 9

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 10

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Tweet 11

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

IPCRG Desktop Helper. Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). May 2020. Accessed March 2, 2022.
<https://www.ipcrg.org/sites/ipcrg/files/content/attachments/2020-06-02/IPCRG%20DH6%20ICS%20COPD%20Rev%20May20.pdf>

Tweet 12

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. *N Engl J Med*. 2020;383:35-48. doi:10.1056/NEJMoa1916046

Tweet 13

Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*. 2014;371:1285-1294. doi:10.1056/NEJMoa1407154

Tweet 16

Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. *Ther Adv Respir Dis*. 2019;13:1753466619884532. doi: 10.1177/1753466619884532

Tweet 17

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2016;2016: Cd006103.
doi:10.1002/14651858.CD006103.pub7

Rigotti NA, Kruse GR, Livingstone-Bank J, Hartmann-Boyce J. Treatment of tobacco smoking: a review. *JAMA.* 2022;327(6):566-577.

Tweet 18

Global Initiative for Chronic Obstructive Lung Disease. 2022 GOLD reports. Accessed June 15, 2022.
<https://goldcopd.org/gold-reports/>

Glossary

AEs, adverse events
BFF, budesonide/formoterol fumarate
BGF, budesonide/glycopyrrrolate/formoterol fumurate
BUD, budesonide
CAT, COPD Assessment Test
COPD, chronic obstructive pulmonary disease
CV, cardiovascular
df, degree of freedom
DM, diabetes mellitus
DPI, dry powder inhaler
DMI, dry mist inhaler
EOS, eosinophils
FEV, forced expiratory volume
FF, free fluids
FM, formoterol fumarate
FP, fluticasone propionate
GFF, glycopyrrrolate/formoterol fumarate
GLY, glycine
GOLD, Global Initiative for Chronic Obstructive Lung Disease
HRQOL, health-related quality of life
IPCRG, International Primary Care Respiratory Group
ICS, inhaled corticosteroid
LABA, long-acting beta-agonists
LAMA, long-acting muscarinic antagonists
LT, long term
MDI, metered dose inhaler
Mgmt, management
mMRC, modified Medical Research Council dyspnea scale
mod-sev, moderate-severe
nAChR, nicotinic acetylcholine receptor

NDRI, norepinephrine and dopamine reuptake inhibitor
NEB, nebulizer
NICE, National Institute for Health and Care Excellence
NRT, nicotine replacement therapy
PCV13, pneumococcal conjugate vaccine
PPSV23, pneumococcal polysaccharide vaccine
pt, patient
QOL, quality of life
RCT, randomized controlled trials
RR, relative risk
SABA, short-acting beta antagonists
SAL, sterility assurance level
SAMA, short-acting muscarinic antagonists
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
SCS, systemic corticosteroids
SGRQ, St. George's Respiratory Questionnaire
SMI, soft mist inhaler
Sxs, symptoms
Tdap, tetanus, diphtheria, and pertussis vaccine
TIO, tiotropium
UMEc, umeclidinium
VI, vilanterol
YO, year old
YOA, years of age
w/d, withdrawal
WHO, World Health Organization
Tx, treatment/therapy